INTRODUCTION
In the People's Republic of China, viral haemorrhagic disease (VHD) of rabbits was first reported as a new entity in 1984 (33) . Rapid spread and early mortality were the principal epidemiological characteristics. In the first stage of VHD spread, the Chinese veterinary services and rabbit industry were alerted to the economic losses caused by VHD. Scientists in the People's Republic of China at once developed inactivated vaccine from infected rabbit tissue treated with formalin. Experimental and field results show that the vaccine can rapidly induce solid immunity against VHD virus (VHDV) infection (14, 30, 41, 50, 56, 57, 63, 70) and that extensive use in the field for prophylaxis has resulted in the control of VHD spread in the People's Republic of China since 1986 (11, 64, 65) . Certain modified adjuvant vaccines have also been developed (16, 32, 46, 70) . In 1990, VHDV was adapted to cultured cells and, according to preliminary immunisation results (36; Ji et al., personal communication), cell culture could possibly be used to develop an inactivated or attenuated vaccine. Hyperimmune antiserum plays an effective part in passive emergency protection and treatment in the field (20, 38, 48, 55, 56, 58) . Since the discovery of a means to control VHD, Chinese scientists have been attempting to clarify the mechanisms of pathogenesis and immunogenesis, and numerous research papers on these subjects have been, and are still being, published in Chinese journals and research collections. This review paper will give a general presentation of this work.
DEVELOPMENT OF VHD VACCINES
When the first outbreaks of VHD were discovered in the People's Republic of China and various antibacterial agents were found to be ineffective in controlling the spread of the disease, it was suggested that the causative pathogen might be a virus. An inactivated tissue vaccine for emergency vaccination was consequently developed, although no knowledge of VHDV characteristics existed. Because quicklyinduced solid immunity can protect vaccinated rabbits from VHDV infection, a national vaccination programme was implemented in areas where VHDV was prevalent. At present, VHD is only found sporadically or is limited, as far as possible, to small areas.
It is evident that VHD is a worldwide disease of economic importance in the rabbit industry (15) . Practical experience with formalin inactivated VHD vaccine for rabbits reveals that the key to controlling the disease is vaccination. Certain modified and improved vaccines are being developed in the People's Republic of China for use, if needed, in sporadically-infected areas or in other countries.
Inactivated tissue vaccines

Seed virus
The virus seeds used for production of inactivated tissue vaccines are liver tissue virus by in vivo serial passages. The virus strains collected from different epidemic regions and in different periods have proved, through vaccine cross protection determination and the haemagglutination inhibition (HI) cross-reaction test (1, 52) , to have the same antigenicity. This explains why the rapid control of VHD spread with the same strain vaccine is possible without having to consider the field-prevalent virus type. Seed virus LD 50 and the haemagglutination (HA) titre are usually higher than 1:10 7 and 1:320, respectively. Seed virus in liver tissue should be stored in a frozen or freeze-dried condition.
Inactivation
The different results obtained in inactivation experiments have been detailed in published papers. Wang et ai. (53) conducted an inactivation test for VHDV strain HC-84 using seven different final concentrations of formalin in the infected liver tissue suspension. The result shows that 1.0-1.4% concentrations could completely inactivate the infectivity of the virus; however, 0.4-0.8% resulted in incomplete inactivation. Identical findings were obtained by Xu (63) , Zhang (74), Wu (57), Zhan (71), Cao (1) and Tong (46) . However, in the study conducted by Li et al., 0.625% formalin inactivation proved effective. The formalin inactivated tissue vaccine has good immunogenicity and no adverse clinical reaction occurs. The vaccine may normally be stored at 4°C for more than one year or at 15°C-20°C for half a year.
Collection of infected tissue
The liver and spleen, and sometimes the kidney, have the highest HA titres in controlled conditions (13) ; these are collected in a sterile state from dying or recently dead rabbits which have been experimentally infected. Five or ten percent suspensions of ground tissues are treated with formalin and then used as vaccine after serial quality control tests. Tenfold dilution of the prepared vaccine also induces solid immunity (46, 51) .
Vaccination
It has been proved that the virus principally infects rabbits older than two months (26, 39) . One of the characteristics of VHD is that younger rabbits are either resistant or infected subclinically (11, 13, 19, 31) . In the laboratory as well as in the field, the author has found that the sturdier rabbits often suffer the highest morbidity and mortality, but that there is no difference in susceptibility between sexes or among breeds (64, 65) . Successful practice in the field with formalin treated tissue vaccine shows that solid immunity may be acquired in adult rabbits. Emergency vaccination can suppress VHD spread within three to four days (42, 57, 63) . Normally, a 1 ml dose is inoculated subcutaneously in the neck of each rabbit. The vaccine is very safe for pregnant rabbits (54) .
Duration of immunity
Numerous challenge tests indicate that immunity in adult rabbits, induced with one dose of the vaccine, may reach a 100% protection rate in the sixth post-vaccination (p.v.) month (46, 50, 56, 73) . In other studies, the duration was found to last until the eighth or ninth month (70) . Thus, it is necessary that breeding and fur-producing rabbits, and those kept for covering, be vaccinated twice a year.
Adjuvant vaccines
Aluminium hydroxide gel vaccine has a potency comparable to non-adjuvant vaccine (46) . However, longer immunity can be induced by the same, or a smaller, dosage of oil-emulsion vaccine. It appears that the HI antibody titres are higher, and duration longer, in rabbits vaccinated with oil-emulsion vaccine than with nonadjuvant vaccine (16, 70) . The use of either alumina gel or oil-emulsion vaccine is advisable because the smaller doses of vaccine are absorbed within one month without any influence upon the quality of the meat and fur. In the twelfth month p.v., the average HI titre for oil-emulsion vaccine is still 1:2 21 , though there is no HI titre for non-adjuvant vaccine (70) .
Combined vaccines
Polyvalent vaccines combined with VHD have been tested successfully in the People's Republic of China. The combined vaccines include bivalent vaccines (VHD/pasteurellosis, VHD/clostridiosis and VHD/bordetellosis) (5, 22, 32, 44, 45) and a trivalent vaccine (VHD/pasteurellosis/clostridiosis) (Y.K. Wang, personal communication). In the combined vaccines mentioned above, the other vaccine components have been found not to influence VHDV immunogenicity, and the VHDV components not to interfere with other vaccine activities. The oil-emulsion combined vaccines induce better and longer protection (32) .
Post-exposure treatment
It is known that vaccinated rabbits quickly produce solid immunity against VHDV infection. When VHD occurs in rabbitries, emergency strategies primarily focus on vaccination of all live rabbits, whether or not they have been infected. It is sometimes found that rabbits with light clinical signs, or with none at all, will recover after emergency inoculation with inactivated tissue vaccine. Huang (21) demonstrated that the majority of rabbits, after having been experimentally infected with a virulent virus for 18 to 24 h and then given three-to fourfold doses of VHD vaccine, could resist VHD, although their recovery from clinical signs took longer. The explanation for this is at present unclear.
Cell-adapted cultured VHDV vaccine
To characterise VHDV and industrialise large-scale production of the vaccine, Chinese laboratories have made many attempts since 1984 to adapt VHDV to cultured cells (2, 36, 47, 59; Ji et al., personal communication). VHDV 7-to 8-passage propagation with cytopathic effect (CPE) has been obtained, respectively, on a newborn rabbit kidney diploid cell and the M-104 cell line. CPE disappears if further propagation is conducted (23, 59) . The mixed suspensions of CPE-positive cultures are inactivated with formalin and used to vaccinate rabbits. The vaccine elicits complete protection with high dosage, but protection is incomplete with normal or low dosage (59). Ji et al. (23) have successfully used a suckling rabbit kidney transformed cell line (DJRK) to propagate VHDV. The immunofluorescent test, the VHD replication test in rabbits and electron microscopic observation have prayed that VHDV can be readily adapted to DJRK. The fifth, tenth (23) and sixteenth (Ji et al., personal communication) passage viruses can still cause typical VHD pathological lesions and death. Inactivated culture suspensions may induce a good immunological response to, and even solid immunity against, VHDV virulent challenge; in addition, the other three cell types (VERO E 6 , LLCMK 2 and L929) have also been used to adapt VHDV successfully. VHDV has been propagated in more than 60 passages (36) . Experiments on cell-adapted VHDV vaccine are now being conducted.
In preliminary experiments on cell-cultured VHDV vaccine, the HI titre in vaccinated rabbits can quickly reach 1:2 10 on the third day p.v. and 1:2 [14] [15] on the seventh to fourteenth days. Progressive drop in the titre starts from the 21st day. On the fourteenth day challenge, 100% protection is observed (23) . The result shows that elicited HI antibody titres are significantly higher at different post-vaccination stages with cell-cultured vaccine than with tissue vaccine. Tests on the duration of immunity are presently being conducted.
Although VHDV has been adapted to cultured cells, the progressive loss of virulence as passage times on cultured cells increase has been found to postpone death in inoculated rabbits (23) . This tendency will result in the possibility of developing an attenuated live VHDV vaccine strain.
VHD PASSIVE IMMUNISATION WITH HYPERIMMUNE ANTISERUM
Hyperimmune antiserum has been successfully used for emergency inoculation in many infectious animal diseases so that endangered animals can quickly produce short-term immunity and infected animals can be treated by neutralising pathogenic agent action. In the People's Republic of China, such attempts have been made for VHD emergency control in the field (20, 22, 38, 55, 56, 57, 58) . It is certain that passively aquired immunity with homogeneous antiserum, which has been extensively used in the field, acts solidly against infection in emergency situations (20, 55, 56, 58) . A dose of 0.2-0.5 ml antisera normally protects against virulent challenge for no less than one month (11, 13) . Passive administration of antiserum is a valuable treatment for infected rabbits with light, or no, clinical signs, but has no effect on dying rabbits. Additionally, some reports indicate that heterogeneous antisera (bovine, ovine and caprine) provide passive protection to some extent, but the cure and protection rates are somewhat lower than those of homogeneous antisera (22, 38, 57) . Traditional Chinese veterinary medicine herbal preparations, injected or administered orally, can enhance nonspecific antiserum treatment and short-term immunity (37) .
Hybridomas which secrete monoclonal antibody (MAb) against VHDV have been identified in several laboratories in the People's Republic of China (34, 35, 36, 72, 76) . It has been proved that three MAbs can protect passively inoculated rabbits from VHDV challenge and that the MAbs are effective in both HI and gel precipitation (72) . So far, there have been no reports on MAb field application in the People's Republic of China.
HISTOPATHOGENESIS AND IMMUNOGENICITY
Histopathogenesis
The pathogenesis of any infectious disease reveals the balance between the ability of the host to resist microbial invasion and the capacity of the microbe to inflict damage. VHD is an acute infection clinically characterised by high fever, haemorrhagic septicaemia, shock and high mortality (11, 33, 64) . Clinical, histopathological and histochemical studies demonstrate that VHDV can replicate at extremely high speed and heavily interfere with the metabolism of target cells and organs (60, 61) . The immune system is one of the most heavily damaged systems. In the spleen and lymph nodes of infected rabbits, the macrophages of different tissues have been observed to phagocytose some red blood cells and necrotic lymphocytes. According to acid alpha-naphthyl acetate esterase (ANAE) staining, T lymphocytes in the blood are significantly reduced in experimentally infected rabbits (3, 18, 72) . The situation continues to deteriorate as the course of the disease develops (18, 72) . The average reduction rate is 37.1% in lymphocytopaenia (Du et al., personal communication) . In addition, T lymphocytes in peripheral lymphatic organs and tissues are destructively influenced (18) . Spleen and lymph nodes become progressively atrophic and the functions of haematopoietic systems are disordered, which are the main causes of lymphocytopaenia and leukocytopaenia (67) . Infected rabbits are therefore unable to mount an effective immune response against the viral infection, and this leads to further deterioration.
Pathophysiological and histopathological reports (24, 29, 60, 67, 75) explain that the VHD virus first invades target systems, including the immune and endothelial systems, and then activates endogenous thrombin pathways. In the 6th h following infection, microthrombi have been observed in the kidney, lung, heart, liver and adrenal tissues. Extensive disseminated intravascular coagulation (DIC) occurs in the parenchymal tissues of dying rabbits (4, 62, 66) .
Rabbit thymus lymphocyte antigen (RTLA) and rabbit bursal equivalent lymphocyte antigen (RABELA) are, respectively, T-cell and B-cell specific markers (6, 15) . In the study by Deng et al. 
Immunological response and immunity
It is known that the capture and treatment of antigen by macrophages, and interaction among macrophages, T cells, B cells and various lymphokines, will induce specific and protective immunity. Additionally, this immunity includes certain nonspecific factors. Some scientists in the People's Republic of China have provided an account of present knowledge, but much remains to be discovered.
Macrophage activity
Capture and phagocytosis of foreign pathogens by macrophages are the first stage in cellular and humoral responses. .5% in the 48th h p.i. (Fig. 1) . In the 72nd and 120th h, the indexes were 16.8 and 45.7%, respectively. The number of engulfed RBCs in a macrophage also rose from 1-2 to 3-5. Only in the 72nd h was a typical RBC-macrophage rose ring formed. The interaction between macrophages and VHDV can greatly reduce phagocytosis and inhibit the rose-ring formation, which suggests that specific contact exists between macrophages and VHDV-coated RBCs. Therefore, it is possible that the binding of macrophage AFC receptors and a few antibodies in the initial stage of vaccination will strengthen macrophage phagocytosis. It is also estimated that macrophages take an active part in the initial anti-viral immunity. The author tried to duplicate in vitro the anti-VHDV-serum mediated VHDV opsonisation, but found no significant phagocytosis and rose-ring formation. The binding may require certain in vivo environmental conditions before macrophage activation starts. 
Dynamic changes in the phagocytic index of three categories of macrophages at different times
Humoral response
Many vaccines can be readily assessed by comparing serum antibody titres before and after immunisation. At present, the established HI test (40) demonstrates well the dynamic change of antibody production (43, 68, 72) , and the relationship between HI antibody titre and protection has also been observed (13, 17, 25, 28, 40, 41, 42, 77) . Because it is simple and convenient to carry out, the method has been widely used to monitor post-immunisation antibody response. Generally, it is thought that HI antibody titre of more than 1:20 is resistant to challenge (41) .
In the studies by Yu et al. (70) , non-adjuvant tissue vaccine and oil-emulsion vaccines were compared in terms of HI antibody response after the first and booster vaccinations (Figs. 2 and 3) . Both vaccines induced typical immunological responses, but the response by oil-emulsion vaccine was stronger than that of non-adjuvant vaccine. Four different inactivated VHD vaccines also showed the same immunological responses (16) . In challenge tests, non-adjuvant vaccine induced the earliest protective immunity on the third day p.i., and all four vaccines conferred the same protection on the seventh day. The duration of immunity of adjuvant vaccines is obviously longer than that of non-adjuvant vaccine (70) . HI antibody anamnetic response after the second vaccination of rabbits with non-adjuvant and oil-emulsion tissue inactivated vaccine (70) Antibody-forming cells (AFC) in the spleen are first detected by the indirect immunofluorescent technique in the 24th h p.i. and in lymph nodes in the 48th h; they then rise continuously in both organs until the 120th h. According to monolayer liquid-phase haemagglutination assay (10), antibody-secreting cells (ASC) first appear in the spleen in the 48th h and in lymph nodes in the 72nd h, and then ASC rapidly increase in quality. In the 120th h, ASC tend to maintain a stable status in the spleen, while in the thymus, lower levels of both AFC and ASC can be observed from, respectively, the 24th and 48th to the 120th h p.i. with no increase occurring. In the appendix, only a very limited number of ASC is measured at the 72nd and 120th h p.i., and no ASC are detected from the 24th to 120th h p.i. among the blood lymphocytes (Fig. 4) (9) . 
Post-immunisation dynamic changes of antibody-forming cells (AFC, a) and antibody-secreting cells (ASC, b) in several lymphatic organs of rabbits immunised with inactivated VHD vaccine
In an experiment involving ten rabbits with no HI-antibody titre, it has been observed (70) that, in the seventh month p.v. with oil-emulsion vaccine, nine still had solid protective immunity against virulent challenge. The rabbits, post challenge, had a significant rise in body temperature; at the same time, HA titre could be detected in the blood. The rabbits recovered and HA titre disappeared in the 72nd h post challenge. It must be pointed out that this situation occurs only in vaccinated rabbits. A rabbit passively immunised, and in which HI antibody disappears, cannot resist the virus challenge (41) . All this illustrates that other factors besides HI antibody participate in protective immunity, which has to be determined by the virus neutralisation test on cell culture. At present, however, HI antibody detection is still used to evaluate and monitor the vaccine effect. In addition, it has been recorded that the indirect haemagglutination test (68, 69) and agarose gel immunodiffusion test (7) have been used for detecting VHD antibodies.
With his colleagues, the author has found that rabbits which have recovered from VHD have a low HI antibody level. When they are vaccinated or re-infected with virulent virus, only a small increase in HI titres can be observed as compared with titres of vaccinated or boosted rabbits. This difference is associated with the virulent damage done to the immune system by the first infection.
In epidemiological investigations, HI antibody can occasionally be detected in rabbit stocks never influenced by an attack of VHD. In addition, low HI antibody titres also exist in some hare (49), calf and human sera (12) . We still do not know whether these HI antibodies are evoked by cross-antigens of other microbes or by VHD virus.
Cellular immunity
Rabbits inoculated with specific transfer factor (TF) prepared from vaccinated rabbit spleen cannot produce effective protection against a challenge in the 18th h post inoculation (28) . In addition, T lymphocyte transformation in the different postvaccination stages is determined by the [ 3 H]-thymidine radioactive (TdR) microdroplet lymphocyte transformation test. The transformation index starts to rise only on the 17th day p.v. (28) . Before that time, humoral response has been evoked in the vaccinated rabbits, indicating that humoral immunity is formed faster than cellular immunity. There is no denying that cellular immunity is important in the immunological response; as with most acute viral diseases, however, VHD immunity is mainly a humoral response.
Role of interferon (IFN)
Interferon is a family of broad-spectrum, nonspecific antiviral products and plays an important role in antiviral responses. According to the cytopathic effect inhibition (CPEI) test, there is a high concentration of IFN in the blood of vaccinated and VHDrecovered rabbits, but only a low level in infected dying rabbits (Fig. 5) . Rabbits administered only with IFN inducer poly-I:C can produce solid short-term protection against virus challenge in the 6th h post administration, while the rabbits used as controls die (27) . The study by Li (28) states that a high concentration of IFN in the blood can interfere with VHDV pathogenesis and provide nonspecific protection. Some virus vaccines have been shown to elicit IFN production quickly, which indicates that IFN contributes to the initial antiviral activities post vaccination; active immunisation will then offer specific and long-term immunity (13) . It has been noticed that, in VHD-recovered rabbits, high-titre IFN peaks in the 18th h following infection.
Individual rabbits which have high levels of IFN or which can produce high titres of IFN very quickly as soon as IFN inducer exists, will usually recover from VHD (27) . The initial immunity induced by inactivated vaccines is associated not only with the fast, specific immunological response, but also with IFN. 
Blood
PROSPECTS
There is little doubt that considerable progress in the molecular biology, immunology, pathology, vaccinology, epidemiology and comprehensive control of VHD has been made since the disease investigated by Liu et al. (33) was first recorded; much, however, remains to be done. Studies on VHD and VHDV are currently at an exciting stage of development, and the author heartily hopes that Chinese scientists and colleagues of other countries and regions will collaborate closely to realise their common objective: to control and, finally, eradicate VHD throughout the world as rapidly as possible.
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